Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

154.72 +5.11 (+3.42%)
Streaming Delayed Price Updated: 3:43 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
56 57 Next >
Should You Sell Your FANGMAN Stocks?
In addition to energy, investors have been fleeing to healthcare stocks for safety. And they have been selling the big tech names, especially the semiconductors. 
Via Talk Markets
Hey Biogen Investors, Don’t Chase BIIB Stock!
If BIIB stock already reflects Biogen's early-stage Alzheimer's disease study results, then the next move could easily be to the downside. 
Via InvestorPlace
Will Investors Notice Exciting Sign On Biogen's Chart?
If history is any guide, there may be good fortune ahead for shares of Biogen (NASDAQ:BIIB). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
2 Signals to Watch Before Buying SAVA Stock
SAVA stock got ahead of itself in September, but if it continues to pull back, a solid entry point could emerge for this risky biotech play. 
Via InvestorPlace
Peering Into Biogen's Recent Short Interest
Biogen's (NASDAQ:BIIB) short percent of float has risen 9.52% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 1.61% of all regular shares that... 
Via Benzinga
Vyant Bio Inc. (NASDAQ: VYNT): Leading a New Biotech Move to Combat Diseases Affecting the Nervous System
Biotechnology companies such as Biogen Inc. (NASDAQ: BIIB),  Alector Inc. 
Via Benzinga
Why Is Biogen (BIIB) Stock Up 40% Today?
Positive results from a clinical trial offer encouragement for the medical community, as well as for downtrodden BIIB stock investors. 
Via InvestorPlace
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio. 
Via Talk Markets
US Supreme Court Turns Away Biogen's Last Effort To Reinstate Tecfidera Patent
The U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen Inc's (NASDAQ: BIIB) blockbuster drug Tecfidera. 
Via Benzinga
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
From Denali Therapeutics Inc.
Via GlobeNewswire
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review
The major indexes fell, with the S&P 500 breaking below bear market lows. 
Via Investor's Business Daily
Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)
From Biogen Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
Netflix, Biogen And Other Big Gainers From Wednesday
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
7 Growth Stocks to Buy to Tap Into a Hidden Bull Market
It's become a bit easier for investors to find growth stocks to buy hidden amid the bear market. 
Via InvestorPlace
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
 
Via Benzinga
Here's How Much $100 Invested In Biogen 20 Years Ago Would Be Worth Today
Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 2.9% on an annualized basis producing an average annual return of 10.93%. Currently, Biogen has a market capitalization of... 
Via Benzinga
Alphabet To $136? Plus This Analyst Slashes PT On United Natural Foods
Truist Securities cut the price target on Alphabet Inc. (NASDAQ: GOOGL) from $145 to $136. Truist Securities analyst Youssef Squali maintained a Buy rating on the stock. Alphabet shares rose 2.5% to... 
Via Benzinga
What The Biogen Chart Reveals As Stock Rallies Hard On Alzheimer's Data
Going back to at least December 2014, Biogen Inc (NASDAQ: BIIB) has been diligently working on drugs to cure Alzheimer's disease. Both the negative and positive data revealed over the years have... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers 
Via Benzinga
Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results
Biogen produced an outstanding Phase 3 result for its Alzheimer’s treatment, sending associated biotech stocks soaring. 
Via InvestorPlace
Why Is Prothena (PRTA) Stock Up 75% Today?
Prothena (PRTA) stock is seeing massive gains on Wednesday despite a lack of recent news from the late-stage clinical company. 
Via InvestorPlace
Why Is Acumen (ABOS) Stock Up 95% Today?
Acumen Pharmaceuticals (ABOS) stock is rocketing higher on Wednesday but it's not due to any recent news from the company. 
Via InvestorPlace
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval
 
Via Benzinga
BMO Capital Upgrades Biogen: Here's What You Need To Know
BMO Capital upgraded its rating of Biogen (NASDAQ:BIIB) to Outperform with a price target of $360.00, changing its price target from $217.00 to $360.00. Shares of Biogen are trading up 37.95% over the... 
Via Benzinga
7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%
Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital... 
Via Benzinga
Why Acumen Pharmaceuticals Stock Is Soaring Today
Acumen Pharmaceuticals Inc (NASDAQ: ABOS) shares are trading higher Wednesday after Biogen Inc (NASDAQ: BIIB) and Eisai Co (Pink: 
Via Benzinga
Why Is Cassava Sciences (SAVA) Stock Heating Up Today?
SAVA stock rose 5% on the success of Biogen in slowing cognitive decline from Alzheimer's, but its Simufilam has a different target. 
Via InvestorPlace
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.